Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Providence Wealth Advisors LLC

Providence Wealth Advisors LLC boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,500 shares of the biopharmaceutical company’s stock after acquiring an additional 612 shares during the period. Bristol-Myers Squibb comprises 1.2% of Providence Wealth Advisors LLC’s investment portfolio, making the stock its 29th biggest holding. Providence Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,323,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its position in shares of Bristol-Myers Squibb by 313.9% during the 1st quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock worth $1,949,043,000 after buying an additional 30,981,844 shares during the last quarter. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $797,038,000. Janus Henderson Group PLC lifted its position in shares of Bristol-Myers Squibb by 15.5% during the 1st quarter. Janus Henderson Group PLC now owns 9,196,512 shares of the biopharmaceutical company’s stock worth $438,767,000 after buying an additional 1,231,639 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Bristol-Myers Squibb by 5.9% during the 4th quarter. Legal & General Group Plc now owns 8,568,445 shares of the biopharmaceutical company’s stock worth $445,300,000 after buying an additional 474,820 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in shares of Bristol-Myers Squibb by 380.2% during the 1st quarter. Nordea Investment Management AB now owns 6,252,847 shares of the biopharmaceutical company’s stock worth $298,324,000 after buying an additional 4,950,748 shares during the last quarter. Institutional investors own 77.60% of the company’s stock.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were purchased at an average price of $47.29 per share, for a total transaction of $236,450.00. Following the completion of the acquisition, the director now owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Karen Murphy Santiago sold 3,065 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the transaction, the insider now owns 3,066 shares in the company, valued at approximately $145,818.96. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.

Shares of BMY stock traded up $0.41 during trading hours on Wednesday, hitting $44.97. 4,079,081 shares of the company were exchanged, compared to its average volume of 13,183,990. The stock has a market cap of $73.02 billion, a price-to-earnings ratio of 11.30, a PEG ratio of 2.07 and a beta of 0.71. Bristol-Myers Squibb Co has a 1 year low of $42.48 and a 1 year high of $63.69. The company has a debt-to-equity ratio of 1.51, a quick ratio of 3.75 and a current ratio of 3.88. The business’s fifty day moving average price is $45.79.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 EPS. As a group, equities research analysts predict that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.41 per share. The ex-dividend date is Wednesday, July 3rd. This represents a $1.64 annualized dividend and a dividend yield of 3.65%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.

Several research firms recently commented on BMY. Goldman Sachs Group set a $27.00 price target on shares of Melco Resorts & Entertainment and gave the company a “buy” rating in a research report on Tuesday, May 28th. Barclays set a $24.00 price target on shares of Orion Engineered Carbons and gave the company a “hold” rating in a research report on Friday, May 3rd. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. JPMorgan Chase & Co. upped their price target on shares of Masonite International from $66.00 to $71.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Finally, BMO Capital Markets began coverage on shares of Yelp in a research report on Wednesday, April 17th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $56.22.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Book Value Per Share – BVPS

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.